This guide is a draft version designed to give guidance to the endTB Project site on the use of new TB drugs bedaquiline and delamanid.
It is intended to be a resource for physicians and other health care professionals involved in the endTB project.
The endTB Medical Committee formulates recommendations for off-label and compassionate use of the new anti-TB drugs for M(X)DR-TB.
It provides advice to any MSF, PIH and IRD projects for individual patient’s management on a case-by-case basis in answer to requests initiated by clinicians from the projects.
For more information, please download the terms of reference.
An overview of MSF’s programmatic use and clinical research with new TB treatment regimens.
Pharmacovigilance forms and other resources for staff on endTB sites.
This 20-page guide is designed to provide all endTB stakeholders with a detailed presentation of the project's four goals.
This MSF Access Campaign report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs.
We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to standardised questionnaires and the Global TB Drug Facility website.
This report was produced with endTB's support.